Painless, Non-Invasive Skin Cancer Treatment Now Available at Doctor’s Approach Dermatology
Doctor’s Approach Dermatology is now treating nonmelanoma (NMSC) skin cancer patients with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, a painless, non-surgical treatment that uses a miniature x-ray source to deliver targeted radiation therapy to cancerous cells while sparing nearby healthy tissue. Compared to traditional radiotherapy, which may require up to 30-35 doses of radiation over the course of 6-8 weeks, this treatment only requires 8-10 doses, each lasting as little as six minutes each.
“The adoption of the Xoft System further validates our long-standing commitment to provide our patients the most advanced technology for their health,” said Dr. Marcy Street, board certified dermatologist, CEO and medical director at Doctor’s Approach Dermatology. “Electronic brachytherapy offers patients many advantages, including the convenience of being treated in the familiarity of their dermatologist’s office, fewer treatments, no pain, and excellent cosmetic results.”
Electronic brachytherapy can be used to treat patients with squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) – the two most common forms of skin cancer. The current standard of care for these types of skin cancers typically includes surgical removal, topical treatments and/or radiation therapy.
The Xoft System delivers non-radioactive (or isotope-free) radiation directly to the skin cancer lesion. Treatments are administered on an outpatient basis and patients are able to resume daily activities immediately. The treatment can be performed in a standard exam room with minimal shielding, allowing medical staff to remain in the room with the patient during treatment.
The Xoft System is FDA cleared to treat cancer anywhere in the body, including skin, vaginal, endometrial, cervical, and early-stage breast cancer. To date, more than 8,000 patients have been treated globally for nonmelanoma skin cancer with the Xoft System.
If you suspect you may have skin cancer, speak with your physician to determine the best treatment approach. For more information, about the Xoft System, visit www.xoftinc.com. For more information or to book an appointment at Doctor’s Approach Dermatology, visit www.doctorsapproach.com.
Normal 0 false false false false EN-US X-NONE X-NONE
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
# # #
For iCAD investor relations inquiries, contact Courtney Dugan of The Ruth Group at 646-536-7024.
For iCAD media inquiries, contact Lynn Granito at Berry & Company at 212-253-8881 or via email at email@example.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Normal 0 false false false EN-US X-NONE X-NONE